Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 1
---
 Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not
Approved” and that the Company published on September 26, 2025.

Broadwood’s analysis is stuck in the past
and does not reflect actual performance today or reasonable expectations going forward. STAAR’s projected 10% growth rate is far below STAAR’s historical 20% growth rate, is based on management’s turnaround plans, and is subject to
significant risks and headwinds.

We are strong believers in the EVO ICL technology and stand behind our plan for STAAR to grow net sales by 10% annually
from 2026 through 2030, but we cannot ignore the challenges that STAAR faces. It is not hard to see from STAAR’s reported results that the Company’s business in China, which represented 51% of consolidated net sales last year, is facing
headwinds. Even a cursory review of STAAR’s financial results reveals that consolidated net sales have been on a downward trajectory since 2023. In spite of STAAR’s challenges, the STAAR Board of Directors succeeded in negotiating a
transaction with Alcon that offers STAAR stockholders a 59% premium to STAAR’s 90-day VWAP and a 51% premium to the closing price of STAAR common stock on August 4, 2025.

Before approving the Alcon agreement, the Board was well aware of Broadwood’s likely objections and carefully considered Broadwood’s perspective on STAAR’s valuation. The Board decided to move forward, despite Broadwood’s objections, because it unanimously concluded that the Alcon agreement is in the best interests of STAAR stockholders. Now, the ultimate decision rests in the hands of all STAAR stockholders, which is exactly where it should be. STAAR does not believe that the Broadwood perspective is shared by the majority of STAAR stockholders and does not believe that Broadwood’s analysis accurately reflects the facts. Broadwood Allegation of “Wrong Process”

| 1. | Broadwood allegation: There is a “Ready pool of logical and well-capitalized buyers” |

| • |     | STAAR Response – Broadwood has an unrealistic view of the buyer landscape |

| • |     | There are only a handful of strategic acquirors in Ophthalmology, all of whom are all well known to STAAR’s 
 Board and management team.                                                                                  |

| • |     | Other than Alcon,